e-learning
resources
Munich 2006
Tuesday 05.09.2006
New modalities and application in imaging of the chest
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Use of PET/CT to evaluate pulmonary inflammation and fibrosis in an animal model
A. Gazdhar, M. Hofmann, T. Krause, R. A. Schmid, T. Geiser (Bern, Switzerland)
Source:
Annual Congress 2006 - New modalities and application in imaging of the chest
Session:
New modalities and application in imaging of the chest
Session type:
Oral Presentation
Number:
3563
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Gazdhar, M. Hofmann, T. Krause, R. A. Schmid, T. Geiser (Bern, Switzerland). Use of PET/CT to evaluate pulmonary inflammation and fibrosis in an animal model. Eur Respir J 2006; 28: Suppl. 50, 3563
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Imaging of complicated pneumonia: what is new?
Imaging of eosinophilic lung disease
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
3he MRI and an animal model of interstitial lung disease
Source: Annual Congress 2009 - Chest imaging in evolution: new techniques and new possibilities
Year: 2009
Nintedanib reduces bleomycin-induced lung inflammation and fibrosis in mice
Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Year: 2013
Molecular imaging of the progression of pulmonary fibrosis using animal models of disease
Source: Eur Respir J 2006; 28: Suppl. 50, 605s
Year: 2006
Measurement of hypoxia in the lung in idiopathic pulmonary fibrosis: an F-MISO PET/CT study
Source: Eur Respir J, 58 (4) 2004584; 10.1183/13993003.04584-2020
Year: 2021
Novel imaging biomarkers for assessment of lung fibrosis and inflammation
Source: Virtual Congress 2021 – Emerging imaging biomarkers in lung disease
Year: 2021
The immunomodulatory effect of protein S in pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
Specialized-proresolving mediators and trancriptomic signatures in bleomycin-induced lung fibrosis
Source: International Congress 2016 – Common mechanisms in lung development and fibrosis
Year: 2016
Animal models of pulmonary emphysema: a stereologist's perspective
Source: Eur Respir Rev 2006; 15: 136-147
Year: 2006
Imaging biomarkers of oedema and fibrosis in a rat model of Drug-Induced-ILD
Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: mechanistic insights and prognostic markers
Year: 2018
Longitudinal assessment of lung fibrosis by micro CT correlates with histological evaluation in bleomycin-induced mice
Source: International Congress 2016 – From microimaging to functional evaluation of the lung
Year: 2016
Biological- and imaging biomarkers of edema and fibrosis in a rat model of drug-induced interstitial lung disease (DIILD)
Source: International Congress 2019 – New mechanistic insights into pulmonary fibrosis
Year: 2019
Effects of NecroX compounds on bleomycin-induced pulmonary fibrosis
Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Year: 2016
Volumetric CT analysis of normal lung as a predictor of mortality in idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
PBI-compound, a novel first-in-class anti-fibrotic compound, reduces lung fibrosis in the bleomycin-induced lung fibrosis model: A comparative study with pirfenidone
Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Year: 2013
The Value of 18F-FDG PET/CT in evaluating disease severity in idiopathic pulmonary fibrosis
Source: International Congress 2017 – ILDs: clinical aspects
Year: 2017
Use of MRI for functional and structural assessment of interstitial lung disease
Source: International Congress 2018 – Emerging and novel imaging biomarkers in drug-induced interstitial lung disease
Year: 2018
The effect of emphysema in patients with idiopathic pulmonary fibrosis; evaluation using quantitative CT analysis
Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Year: 2016
Use of pulmonary proteomics to investigate lung disease
Source: Annual Congress 2004 - PG7 - Application of genomics and proteomics to pulmonary disease
Year: 2004
Lung functions and imaging characteristics of the patients with combined pulmonary fibrosis and emphysema
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015
Interstitial pulmonary fibrosis model develpment and identification of early biomarkers by MALDI imaging
Source: International Congress 2015 – New insights into IIPs
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept